FDA approves ozempic for type 2 diabetes

December 6, 2017

(HealthDay)—A new once-weekly diabetes medication that lowers blood glucose and also helps patients lose weight has been approved by the U.S. Food and Drug Administration.

The once-a-week injection drug Ozempic (semaglutide) is approved for patients with type 2 diabetes. It stimulates the body's and reduces appetite, the Associated Press reported.

The drug is from Danish company Novo Nordisk. A company-funded study of 1,200 type 2 found those who took Ozempic had average reductions in long-term levels at least 2.5 times greater than those who took daily sitagliptin.

Patients who took Ozempic also lost two to three times as much weight as those in the comparison group, the AP reported.

Explore further: Ozempic approved for type 2 diabetes

More information: More Information

Related Stories

Ozempic approved for type 2 diabetes

December 6, 2017
(HealthDay)—Ozempic (semaglutide) has been approved by the U.S. Food and Drug Administration as a weekly injection to treat type 2 diabetes in adults.

Diabetes pill might replace injection to control blood sugar

October 17, 2017
(HealthDay)— An injectable class of diabetes medication—called glucagon-like peptide-1 or GLP-1—might one day be available in pill form, research suggests.

FDA approves two new medications for diabetes

September 29, 2015
(HealthDay)—Two new diabetes treatments, Tresiba (insulin degludec injection) and Ryzodeg (insulin degludec/insulin aspart injection), have been approved by the U.S. Food and Drug Administration.

Danish drugmaker reaches settlement with US authorities

September 6, 2017
Danish drug maker Novo Nordisk says it has reached a $46.5 million settlement with U.S. authorities over allegations that it hadn't properly communicated safety information when marketing a medicine to treat type 2 diabetes.

Trial shows drug can dramatically reduce weight of people with obesity

October 23, 2017
A drug that targets the appetite control system in the brain could bring about significant weight loss in people with clinical obesity, according to new research.

FDA clears Novo Nordisk's weight loss drug Saxenda

December 23, 2014
The Food and Drug Administration has approved a Novo Nordisk diabetes drug as a treatment for obesity. It's the first injectable drug approved for weight loss.

Recommended for you

Researchers find existing drug effective at preventing onset of type 1 diabetes

February 15, 2018
A drug commonly used to control high blood pressure may also help prevent the onset of type 1 diabetes in up to 60 percent of those at risk for the disease, according to researchers at the University of Colorado Anschutz ...

Chemist designs diabetic treatment minus harmful side effects

February 9, 2018
A chemist in the College of Arts and Sciences (A&S) has figured out how to control glucose levels in the bloodstream without the usual side effects of nausea, vomiting or malaise.

Peptide improves glucose and insulin sensitivity, lowers weight in mice

February 8, 2018
Treating obese mice with catestatin (CST), a peptide naturally occurring in the body, showed significant improvement in glucose and insulin tolerance and reduced body weight, report University of California San Diego School ...

Study reports use of nutritional ketosis with mobile app intervention could reverse Type 2 diabetes

February 7, 2018
A newly published study has shown that an individualized approach to nutritional ketosis (utilizing fat rather than glucose to fuel the body), combined with remote monitoring via a mobile application, could sustainably and ...

Simple molecule could prevent, alleviate pre-diabetes

February 7, 2018
Restoring levels of coenzyme Q10 (CoQ), a key molecule in energy production in cells, could overcome insulin resistance or pre-diabetes—a precursor to type 2 diabetes and cardiovascular disease.

Brain scans show why some type 1 diabetics miss low blood sugar cues

February 2, 2018
The brains of people with type 1 diabetes react differently to low blood sugar compared with healthy adults, say Yale researchers.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.